Skip to main content

Table 1 Base case settings of the BIM

From: Budget impact assessment of Aprokam® compared with unlicensed cefuroxime for prophylaxis of post-cataract surgery endophthalmitis

Variables

Details

Country and perspective

United Kingdom; NHS and PSS perspective

Currency

GB 2013 £

Time horizon

5 years

Intervention

Aprokam vials of 50 mg, reconstituted into one single 1 mg/0.1 mL individual dose administered intracamerally by slow injection into the anterior chamber of the eye [9]. Resource utilisation inputs used in the model for the reconstitution of Aprokam follow the Aprokam SPC guidelines [9]

Comparators

PFS of cefuroxime prepared in the pharmacy hospital, using Zinacef 750 mg vials

Refrigerated ready-to-use PFS purchased by the hospital from manufacturers

Number of cataract surgeries in first year

Hypothetical cohort of 1000 cataract surgeries performed in the first year

Annual increase in cataract surgeries

Annual increase of 5.2 % in the number of cataract surgeries. This is based on the average annual increase in the number of cataract surgeries performed within the NHS in England between 1998 and 2009, as reported by The Royal College of Ophthalmologists [6]

  1. BIM: budget-impact model; GB: Great Britain; NHS: National Health Service; PFS: pre-filled syringes; PSS: Personal Social Services; SPC: Summary of Product Characteristics